Navin Fluo.Intl.Q1 FY27
Navin Fluo.Intl. Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹8,137P/E: 52.9Market Cap: ₹42.1K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- →Growth till FY '28 is largely baked in due to ongoing capex, including new HFC capacity, debottlenecking plant, and Chemours project.
- →Advanced materials vertical is being incubated to become a material business unit by the decade's end, focusing on high-growth sectors like data centers, electronics, defense, and semiconductors.
- →Specialty chemicals expected to grow with good order visibility and ramp-up in existing/new molecules, despite pricing pressures, especially in Latin America.
- →CDMO business shows strong momentum with an expanding portfolio of commercial, late-stage, and early-stage programs across therapeutic areas including oncology, respiratory, cardiovascular, neurology, and animal health.
- →New molecule pipeline of 30-40 molecules under active development, with 3-4 molecules expected FDA readouts in 8-12 months.
- →Contractual discussions ongoing for long-term supply agreements (e.g., 35-45% of R32 capacity contracted).
- →Overall, sustainable growth expected fueled by disciplined capex, customer engagement, and product innovation.
Margin guidance
Category 3- →Navin Fluorine expects continued strong growth across its business verticals—HPP, Specialty Chemicals, and CDMO—with robust order pipelines and product launches.
- →FY '27 growth is backed by ongoing capex (including INR90 crores in advanced materials) leading to capacity expansions and commercial scale-up.
- →EBITDA margins are targeted in the range of 32-33% (+/- 1%) over the next 1-2 years, supported by operating leverage from new capacities.
- →CDMO business anticipates further depth with multiple late-stage FDA readouts over 8-12 months, supporting sustained revenue growth.
- →Advanced materials business aims to become a material business unit by decade-end, contributing accretively to margins and profits.
- →Past capex of INR3,000 crores and upcoming ~INR3,000 crores enable solid growth visibility through FY '28 and beyond, locking in revenue streams and order visibility.
- →Overall, disciplined investments, productivity gains, pricing strategies, and diversified product mix create confidence for sustained earnings expansion and improved EPS.
3 more insights locked — sign up free to unlock
Fundraise plans
- →There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
- →The company highlights that the INR90 crores capex for advanced materials and INR125 crores Phase 2 CDMO capex are being funded through internal accruals.
- →The company has become net debt free during the quarter.
- →Emphasis is on disciplined investment and funding capex via internal accruals rather than external financing.
- →No indications of upcoming equity or debt issuance were discussed in the Q1 FY '27 earnings call.
Order book
- →Navin Fluorine is actively working on a molecule pipeline of 30 to 40 molecules.
- →About 10 molecules are in the late stage, with 3 to 4 expected to have FDA readouts in the next 8 to 12 months.
- →The company has strong order visibility in the Specialty Chemicals segment with existing and new molecules.
- →CDMO business shows improved visibility with a robust product pipeline and sustained momentum.
- →New capacity for CDMO is dedicated to existing European CDMO partner, with expansion in supply chain participation through MSAs.
- →The company also has upcoming orders related to DRDO, but details remain confidential.
- →Contractual commitments for R32 are in advanced conversations to secure 35%-45% of total capacity over the next five years.
- →Overall, Navin only pursues capex with sufficient revenue visibility and value-accretive opportunities.
Capex plans
Yes- →INR 90 crores capex approved for setting up adoption capacities for the advanced materials business, funded through internal accruals. This will cater to indigenous products for emerging sectors like data centers, electronics, defense, and semiconductors. (To be completed by Q2 FY '28)
- →Chemours project as part of advanced materials vertical, targeted for completion by end of Q2 FY '27.
- →Phase 2 cGMP4 capex of INR 125 crores in CDMO business funded through internal accruals, expected operationalization by Q4 FY '27. Part of INR 288 crores cGMP4 capex approved earlier.
- →HFC capacity expansion equivalent to 15,000 metric tons of R32 on track for commissioning in Q3 FY '27.
- →MPP facility debottlenecking at Dahej expected to complete by Q3 FY '27.
- →INR 15.73 crores investment in a 14.9 MW captive hybrid renewable energy project to meet 60%+ of energy needs, supporting sustainability goals.
- →Focus on capital discipline and technology-driven growth with multiple capacity expansions underway.
How does Navin Fluo.Intl. rank vs peers in Chemicals & Petrochemicals?
Pro feature1Navin Fluo.Intl.
Rev 2Mar 3
See full Chemicals & Petrochemicals sector rankings
How does Navin Fluo.Intl. rank in Chemicals & Petrochemicals?
Compare Navin Fluo.Intl. against every Chemicals & Petrochemicals company (Q1 FY27) on revenue, margins and earnings-call signals.